A Comparison of Dabigatran With Warfarin for Stroke Prevention in Atrial Fibrillation in an Asian Population. (November 2016)

• Record Type: Journal Article
• Authors: Yap, Lok Bin; Eng, Daniel Theng Sheng; Sivalingam, Lingghesh; Rusani, Beni Isman; Umadevan, Dhanan; Muhammad, Zulkeflee; Koh, Kok Wei; Aisha, Barveen; Hashim, Mohd Irwan; Rebo, Rosila; Hussin, Azlan; Kaur, Surinder; Shanmugam, Rajasingam; Omar, Razali
• Is Part Of: Clinical and applied thrombosis/hemostasis. Volume 22:Number 8(2016)
• Page Start: 792
• Page End: 797
• Publication Date: 2016-11
• Subjects: non-valvular atrial fibrillation -- novel anticoagulant -- stroke prevention -- dabigatran -- warfarin; Hemostasis -- Periodicals; Thrombosis -- Periodicals; 616.13
• DOI: 10.1177/1076029615584664
• Languages: English
• ISSNs: 1076-0296

Abstract

Background: The Asian population with atrial fibrillation (AF) have a higher risk of stroke than the caucasian population and a higher risk of intracranial bleeding when anticoagulated with warfarin. There are few real-world studies comparing the efficacy of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin among Asian patients to assess its outcomes of ischemic stroke and hemorrhagic stroke. Methods: A retrospective cohort study of 1000 patients on dabigatran and warfarin from 2009 to 2013. Results: Data were available for 500 patients on dabigatran and 500 patients on warfarin. The average follow-up duration was 315 ± 280 days in the dabigatran group and 355 ± 232 in the warfarin group. The time in therapeutic range (TTR) was 53.2% in the warfarin-treated group, with 32.8% of patients in the subtherapeutic international normalized ratio range of <2. None of the patients in the dabigatran group had ischemic cerebrovascular accident (CVA) compared to 4 (0.8%) patients in the warfarin group, hazard ratio (HR) 0.13, P = .3. There was 1 (0.2%) patient in both dabigatran and warfarin groups with hemorrhagic CVA (HR 1.16, P = .92). There were 3 (0.6%) patients with major bleeding in the dabigatran group compared to 2 (0.4%) patients in the warfarin group (HR 1.57, P = .59). Conclusion: There were similar rates of efficacy for outcomes of ischemic CVA, hemorrhagic CVA, and bleeding when comparing dabigatran with warfarin. Our study shows that despite similar efficacy, suboptimal TTR rates and inconveniences with warfarin demonstrate that NOACs are preferred for stroke prevention in AF.